Medial preoptic-anterior hypothalamic area involvement in the suppression of pulsatile LH release by a mu-opioid agonist in the ovariectomized rat.
The objective of this study was to examine whether specific activation of mu-opioid receptors at the level of the medial preoptic-anterior hypothalamic area (MPOA-AHA) could suppress pulsatile LH release. The experiments were done using rats that had been ovariectomized (OVX) 24 hr before on diestrus 2, animals in which we have previously demonstrated an active endogenous opioid peptide suppression of pulsatile LH release (2). DAGO, DPDPE, or U50488H, specific agonists of mu-, delta- and kappa-opioid receptors, respectively, were continuously applied directly to the MPOA-AHA by means of push-pull perfusion. Perfusion of the MPOA-AHA with 0.5 micrograms DAGO/hr suppressed LH pulse amplitude. This effect of DAGO was not due to spread to the third ventricle and subsequent diffusion via the CSF to another CNS site, since push-pull perfusion with this dose of DAGO in the region just dorsal to or in the posterior hypothalamus was ineffective in altering LH pulse amplitude. The response to DAGO was dose-dependent since a higher dose (4.8 micrograms/hr) markedly suppressed both LH pulse amplitude and frequency. The same doses of DPDPE and U50488H (0.5 and 4.8 micrograms/hr) had no effect on pulsatile LH secretion, providing support for mu receptor involvement in the DAGO-induced suppressive action. These data demonstrate MPOA-AHA involvement in the suppression of pulsatile LH release by a mu-opioid agonist in the OVX rat.
Mallory
D S
DS
Department of Physiology and Neurobiology, University of Connecticut, Storrs 06269.
Gallo
R V
RV
D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D000818:Animals; D007025:Anterior Hypothalamic Nucleus / Q000187:drug effects / Q000502:physiology*; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D020881:Enkephalin, D-Penicillamine (2,5)-; D004745:Enkephalins / Q000494:pharmacology*; D005260:Female; D007700:Kinetics; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D010052:Ovariectomy; D011301:Preoptic Area / Q000187:drug effects / Q000502:physiology*; D011759:Pyrrolidines / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D011957:Receptors, Opioid / Q000187:drug effects / Q000502:physiology*; D017450:Receptors, Opioid, mu; D013997:Time Factors
D004745:Enkephalins; D011759:Pyrrolidines; D011957:Receptors, Opioid; D017450:Receptors, Opioid, mu; D020875:Enkephalin, Ala(2)-MePhe(4)-Gly(5)-; D019900:3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; D020881:Enkephalin, D-Penicillamine (2,5)-; D007986:Luteinizing Hormone